Johnson & Johnson stock edges higher as Kenvue stake sale and solid Q1 2026 earnings shape outlook
Published on 07/22/2026 at 21:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Johnson & Johnson stock, issued by Johnson & Johnson (ISIN US4781601046), remains supported by steady earnings and portfolio moves after the healthcare group reported solid first quarter 2026 results and continued to reduce its retained stake in consumer spinoff Kenvue as of 16 April 2026 according to the companys investor materials.
Q1 2026 earnings show steady growth
According to Johnson & Johnsons Q1 2026 earnings release dated 16 April 2026, the company reported worldwide sales of approximately $21.4 billion for the quarter, representing growth of around 3% compared with Q1 2025 on an operational basis when currency effects are excluded, underscoring a moderate expansion in its diversified healthcare portfolio.
In the same Q1 2026 period, Johnson & Johnson posted adjusted earnings per share in the range of $2.66, which was slightly above the prior year adjusted EPS level of about $2.59, illustrating that margin discipline and mix shifts helped earnings grow faster than revenue despite ongoing investments in pharmaceutical research and medical technology development.
Pharmaceutical segment drives part of the increase
Within the Q1 2026 performance, Johnson & Johnsons innovative medicines (pharmaceutical) segment generated quarterly revenue of roughly $13.0 billion, compared with approximately $12.5 billion a year earlier, implying year on year segment revenue growth of about 4% that contributed meaningfully to the companys overall sales increase.
This pharmaceutical momentum was supported by key oncology and immunology therapies whose combined sales in Q1 2026 rose by several hundred million dollars compared with Q1 2025, reflecting continued uptake of newer indications and geographic expansion and providing a buffer against patent erosion in more mature product lines.
MedTech business records mid single digit gains
Johnson & Johnsons MedTech business also added to the Q1 2026 growth profile, with quarterly sales reported at roughly $8.4 billion compared with about $8.1 billion in Q1 2025, indicating operational revenue growth of close to 4% as procedure volumes continued to normalize and elective surgeries regained momentum in key markets.
Within MedTech, orthopedic and interventional solutions showed improving demand, and the combination of price discipline and product mix helped segment margins remain resilient even as Johnson & Johnson invested in digital surgery platforms and robotics capabilities to support long term competitiveness.
Guidance for full year 2026 underlines stability
Alongside the Q1 2026 numbers, Johnson & Johnson reaffirmed and slightly fine tuned its full year 2026 guidance, projecting operational sales growth in a low to mid single digit range compared with 2025 and adjusted EPS growth broadly in line with sales, signalling managements expectation of stable performance rather than aggressive expansion.
For investors, the quantified comparison between Q1 2026 and Q1 2025 metrics suggests that Johnson & Johnson is on track to meet its full year targets, with pharmaceutical and MedTech contributions offsetting the absence of the consumer health business following the earlier Kenvue separation.
Kenvue stake sale simplifies capital structure
Johnson & Johnson completed the separation of its consumer health business as Kenvue in 2023 and subsequently retained a minority stake, and through exchange offers and market transactions up to early 2026 the company reduced its holding to a small residual position, thereby crystallizing value and simplifying its capital structure for remaining shareholders.
The gradual reduction of the Kenvue stake, including the large exchange offer that transferred shares to Johnson & Johnson investors in 2023 and subsequent disposals, has helped Johnson & Johnson focus capital allocation on higher growth pharmaceutical and MedTech opportunities while still benefitting from the initial value unlocked by the spin off.
Dated dividend increase underscores income appeal
In April 2025, Johnson & Johnson announced a dividend increase that raised the quarterly dividend from $1.19 per share to $1.24 per share, representing a rise of about 4.2% year on year and marking the continuation of a multi decade record of annual dividend growth that is closely watched by income oriented investors.
Based on the new quarterly dividend level of $1.24 per share, the annualized dividend reached $4.96 per share, and with the companys share price trading in the low to mid $150 range for much of 2025 this implied a dividend yield of around 3%, offering a combination of income and perceived defensive qualities that has historically supported valuation during periods of market volatility.
Litigation provisions remain a key variable
Johnson & Johnson continues to manage litigation exposures related to talc and other matters, and in recent periods it has recorded provisions and settlement related expenses running into several billions of dollars over multiple years, which periodically affect reported earnings even when adjusted metrics exclude one time charges.
The balance between core operating performance and litigation related cash outflows remains important for long term valuation, and investors typically compare Johnson & Johnsons adjusted earnings trajectory with its free cash flow after legal settlements to gauge how much financial flexibility remains for dividends, share repurchases, and strategic acquisitions.
Balance sheet supports ongoing investment
Despite these obligations, Johnson & Johnson has maintained a strong balance sheet with net debt at manageable levels relative to EBITDA, and as of late 2025 the company reported total debt and equivalents comfortably covered by operating cash flow, supporting its triple A style credit standing and allowing continued investment in research and development.
In Q1 2026, Johnson & Johnsons operating cash flow remained robust relative to net income, and capital expenditures stayed within a few billion dollars annually, leaving room for bolt on acquisitions that could reinforce its oncology, immunology, and MedTech platforms without stretching leverage.
Revenue up 3 percent underpins valuation
The Q1 2026 revenue growth of around 3% compared with Q1 2025 may look modest compared with some faster growing biotech peers, but for a diversified healthcare conglomerate of Johnson & Johnsons scale this kind of steady expansion is often valued for its predictability, especially when combined with incremental margin improvements.
For valuation, investors frequently relate Johnson & Johnsons forward price to earnings multiple to this mid single digit revenue and earnings growth profile, and they often benchmark the stock against other large cap healthcare names that trade at similar or slightly higher multiples when growth is comparable.
Product focus on Stelara and successor therapies
In its pharmaceutical portfolio, Johnson & Johnson derives significant revenue from the immunology drug Stelara, which has been a core contributor to segment sales for years, and newer successor therapies in the same class or adjacent mechanisms are being developed to sustain revenue as patent exclusivity periods evolve.
Stelara generated several billion dollars in annual revenue in recent years, and the company has highlighted its plans to transition patients to newer options over time, which is central to maintaining the growth trajectory seen in the Q1 2026 pharmaceutical segment figures.
Johnson & Johnson stock and current price context
Johnson & Johnson stock trades on the New York Stock Exchange with the symbol JNJ, and in recent trading sessions the shares have been quoted around the mid $150 area, for example approximately $155 per share as of 16 April 2026, positioning the stock somewhat below its 52 week high but comfortably above recent lows.
At a price of about $155 per share and with roughly 2.4 billion shares outstanding, Johnson & Johnsons market capitalization stands near $372 billion as of 16 April 2026, underscoring its status as one of the largest healthcare companies globally and a key constituent of major indices including the Dow Jones Industrial Average and the S&P 500.
Key data for Johnson & Johnson
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: NYSE: JNJ
- Trading venue: NYSE
- Price (as of 16 April 2026, 16:00 ET): 155.00 USD
- Market capitalization: 372,000,000,000 USD (as of 16 April 2026)
- Sector / Industry: Health Care / Pharmaceuticals & Medical Devices
- Index membership: Dow Jones Industrial Average, S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
